kabutan

Perseus Proteomics Inc.(4882) Summary

4882
TSE Growth
Perseus Proteomics Inc.
258
JPY
-19
(-6.86%)
Mar 13, 3:30 pm JST
1.61
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
255.3
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.73
Yield
ー%
Margin Trading Ratio
816.02
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
266 JPY 1.67 USD
Previous Close Mar 12
277 JPY 1.74 USD
High Mar 13, 9:03 am
266 JPY 1.67 USD
Low Mar 13, 9:07 am
250 JPY 1.57 USD
Volume
1,817,300
Trading Value
0.47B JPY 2.93M USD
VWAP
256.98 JPY 1.61 USD
Minimum Trading Value
25,800 JPY 161 USD
Market Cap
3.81B JPY 0.02B USD
Number of Trades
1,483
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
864
1-Year High Mar 9, 2026
13,130
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 1,367,400
Feb 27, 2026 0 1,329,700
Feb 20, 2026 0 1,322,700
Feb 13, 2026 0 1,355,400
Feb 6, 2026 0 1,402,800
Company Profile
Perseus Proteomics Inc. is a biotech venture company specializing in the development of high-performance antibody drugs and research reagents targeting cancer.
Sector
Pharmaceuticals
Perseus Proteomics Inc. is a biotech venture company that leverages its academic drug discovery network originating from the University of Tokyo to conduct research and development of antibody drugs. Utilizing proprietary antibody acquisition and engineering technologies, the company is advancing the development of therapeutic antibodies targeting cancer and hematological diseases. Its main pipeline includes PPMX-T002, a radioisotope-labeled antibody targeting cadherin 3, and PPMX-T003, an antibody targeting transferrin receptor 1. The company's revenue is derived from upfront payments from out-licensing drug candidates to domestic and international pharmaceutical companies, milestone payments based on development progress, and royalty income as a percentage of sales after market launch.